Module 1 - Understanding the Pathophysiological Complexity of Obesity and Comorbidities

Dr. A.G. (Onno) Holleboom MD PhD is an associate professor and internist in Vascular Medicine and Endocrinology at Amsterdam UMC, The Netherlands. He heads a multidisciplinary outpatient clinic for metabolic dysfunction-associated steatotic liver disease (MASLD) together with hepatology. Supported by the Dutch gastroenterology and hepatology foundation, his team investigates and implements care paths for MASLD. He is on the executive board of the Innovative health Initiative (IHI) GRIP-on-MASH consortium, has co-authored the 2024 Dutch MASLD guideline and was on the Delphi panel for the EASL-EASD-EASO MASLD 2024 guideline. He runs a research group with 6 PhD candidates focusing on the genetic and gut microbial drivers of MASLD and on pathways around liver sinusoidal endothelium.

Naveed Sattar graduated from the University of Glasgow in 1990. In early 1992, he took up his first post as a senior house officer (SHO) at Edinburgh Royal Infirmary; returning to Glasgow later that year as an SHO at the Victoria Infirmary. In 1993, he moved to Glasgow Royal Infirmary, first as a Specialist Registrar, then as Senior Lecturer and Reader. He was awarded a PhD from the University of Glasgow in 1998.

He joined the staff of the University of Glasgow and in early 2005, was appointed as Professor of Metabolic Medicine at the Institute of Cardiovascular & Medical Sciences (now School of Cardiovascular and Metabolic Health). He continues as an Honorary Consultant in Metabolic Medicine at the Glasgow Royal Infirmary, where he co-leads a CVD prevention clinic. He is a Fellow of the Royal College of Pathologists; the Royal College of Physicians and Surgeons, Glasgow; the Royal Society of Edinburgh; and the UK Academy of Medical Sciences.

He is regularly asked to speak at international conferences and has sat on several national and international guideline committees, including the European Society of Cardiology (ESC) Task Force to develop 2023 Guidelines on diabetes and cardiovascular disease; the Joint British Societies 3 CVD prevention recommendations; the SIGN obesity and CVD prevention guidelines (latter as Chair); and the European CVD prevention guidelines. In later 2023 he was appointed as the UK Government’s new Obesity Mission Chair.

He has epidemiology, mechanistic and trial expertise in diabetes, obesity and cardiovascular disease, having contributed to several lifestyle (e.g. DIRECT, STANDBY, UPBEAT, EUROFIT) and drug (e.g. REMOVAL, TRUST, AMPLITUDE-O, EMPEROR heart failure) trials, with ongoing activity in several outcome trials. He is an Associate Editor for Diabetes Care and is on the editorial boards for BMC Medicine and Diabetes & Metabolic Syndrome: Clinical Research & Reviews. He has previously been an Associate Editor for Circulation and sat on committees for Diabetologia, Diabetes Digest, Diabetes UK, European Association for Study of Diabetes (EASD), Lancet Diabetes and Endocrinology, American Diabetes Association, Scotland’s Chief Scientist Office, British Heart Foundation, and UK Biobank.

He has authored / co-authored over 1200 published papers and has been cited more than 120k times (Web of Science) and >200K (Google scholar). He has been in the top 1% of cited clinical academics in the world since 2014, according to the annual Clarivate Analytics Highly Cited Researcher list. He has received several national and international prizes for his research, including the following lectures: Banting Memorial, Camillo Golgi, Dorothy Hodgkin, Minkowski, John French Rank Nutrition, and the and the RD Lawrence Lecture.